Embecta Corp. (EMBC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1,086 | 1,165 | 1,130 | 1,121 | 1,123 | 1,080 | 1,019 | 1,024 |
| Operating profit | $m | 329 | 253 | ||||||
| Net profit | $m | 428 | 415 | 224 | 70 | 78 | 95 | 88 | 107 |
| EPS reported | $ | 1.62 | 1.48 | ||||||
| Operating cashflow per share | $ | 3.29 | 2.98 | ||||||
| Capex per share | $ | 0.16 | 0.16 | ||||||
| FCF per share | $ | 3.13 | 2.81 | ||||||
| Free cash flow | $m | 182 | 165 | ||||||
| Net debt | $m | 1,173 | 1,247 | ||||||
| Book value equity | $m | -651 | -613 | ||||||
| Book value per share | $ | -11.05 | -10.47 | ||||||
| Number of shares | m | 58.92 | 58.51 | ||||||
| DPS (TTM paid) | $ | 0.60 | 0.32 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 8.71 | 4.01 | ||||||
| P/B LTM | x | -1.26 | -1.34 | ||||||
| P/S LTM | x | 0.76 | 0.81 | ||||||
| P/FCF LTM | x | 4.51 | 5.00 | ||||||
| EV/EBITDA LTM | x | 6.88 | 7.41 | ||||||
| EV/Sales LTM | x | 1.88 | 1.54 | ||||||
| Earnings Yield LTM | % | +11.48% | +24.94% | ||||||
| FCF Yield | % | +22.17% | +20.01% | ||||||
| Quality | |||||||||
| ROE | % | -14.65% | -13.98% | ||||||
| ROIC | % | +27.36% | +17.92% | ||||||
| Operating margin | % | +30.48% | +24.85% | ||||||
| Gross margin | % | +62.89% | +59.89% | ||||||
| FCF/Sales | % | +16.88% | +16.16% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +20.90% | +10.45% | ||||||
| Sales Growth YoY | % | -3.80% | -9.30% | ||||||
| Net Income Growth YoY | % | +21.84% | +11.75% | ||||||
| FCF Growth | % | +816.58% | +727.14% | ||||||
| Operating Profit Growth | % | +89.04% | +45.29% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +4.25% | +9.02% | ||||||
| Dividend Growth | % | 0.00% | -46.67% | ||||||
| Payout Ratio | % | +36.67% | +31.25% | ||||||
| FCF/Debt | x | 0.13 | 0.11 | ||||||
| Net Debt/EBITDA | x | 4.09 | 4.64 | ||||||
| EBIT/Net interest | x | 3.07 | 2.62 | ||||||
| Net debt/market cap | % | +1.70% | +4.81% | ||||||
| Net debt/Equity | x | -1.80 | -2.03 | ||||||
| Gross debt/equity | x | -2.20 | -2.45 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free